Current Problems in Surgery
Volume 46, Issue 1 , Pages 13-106 , January 2009

The Zollinger-Ellison Syndrome: A Comprehensive Review of Historical, Scientific, and Clinical Considerations

  • E. Christopher Ellison, MD

      Affiliations

    • Associate Vice-President for Health Sciences, Vice-Dean for Clinical Affairs, Robert M. Zollinger Professor, Chair, Department of Surgery, Ohio State University Medical Center, Columbus, Ohio
    • ,
  • Jerome A. Johnson, PhD

      Affiliations

    • Administrator, Department of Surgery, Ohio State University Medical Center, Columbus, Ohio

References 

  1. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg. 1955;142:709–728
  2. Zollinger RM, Coleman DW. The Influences of Pancreatic Tumors on the Stomach. Springfield, IL: Charles C. Thomas; 1974;
  3. Ellison EH. The ulcerogenic tumor of the pancreas. Surgery. 1956;40:147–170
  4. Gregory RA, Tracy HJ, French JM, et al. Extraction of a gastrin-like substance from a pancreatic tumor in a case of Zollinger-Ellison syndrome. Lancet. 1960;1:1045–1048
  5. Underdahl LO, Woolner LB, Black BM. Multiple endocrine adenomas: report of 8 cases in which the parathyroids, pituitary, and pancreatic islets were involved. J Clin Endocrin Metab. 1953;13:20–24
  6. Wermer P. Genetic aspects of adenomatosis of the endocrine glands. Am J Med. 1954;16:363–371
  7. Oberhelman HA, Nelson TS. Surgical considerations in the management of ulcerogenic tumors of the pancreas and duodenum. Am J Surg. 1964;108:132–141
  8. Berson SA, Yalow RL. Immunoassay of endogenous insulin in man. J Clin Invest. 1960;39:1157–1175
  9. McGuigan JD, Trudeau WL. Immunochemical measurement of elevated levels of gastrin in the serum of patients with pancreatic tumors of the Zollinger-Ellison variety. N Engl J Med. 1968;278:1308–1313
  10. Isenberg JI, Walsh JH, Passaro E, et al. Unusual effect of secretin on serum gastrin, serum calcium, and gastric acid secretion in a patient with suspected Zollinger-Ellison syndrome. Gastroenterology. 1972;62:626–631
  11. Stabile BE, Morrow DJ, Passaro E. The gastrinoma triangle: operative implications. Am J Surg. 1984;147:25–31
  12. Thompson NW, Vinik AI, Eckhauser FE. Microgastrinomas of the duodenum (A cause of failed operations for the Zollinger-Ellison syndrome). Ann Surg. 1989;209:396–404
  13. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome?. Ann Surg. 2004;239:617–625
  14. Beaumont W. Experiments and Observations on the Gastric Juice and the Physiology of Digestion. Flattsburg: F. P. Allen; 1833;
  15. Khizhin P. Activite secretoine de l'estomac du chien. Arch Sci Biol (St. Petersburg). 1894;3:461–469
  16. Lobasov IO. Sur l'excitabilite secretoire specifique de la muqueuse du canal digestif. Arch Sci Biol (St. Petersburg). 1897;5:425–437
  17. Lecorte P. Functions gastrointestinales etude physiologique. La Cellule. 1900;17:283–296
  18. Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol. 1902;28:325–353
  19. Edkins JS. On the chemical mechanism of gastric secretion. Proc R Soc. 1905;76:376–391
  20. Gross W, Pavlov I. Contribution to the conditions of gastric secretion according to experiments on the dog. Arch f Vendauungshnank. 1906;12:507–528
  21. Maydell BE. The question of the gastric secretion. Pfluger's Arch. 1913;150:390–404
  22. Tomaszewski Z. Uber die chemischen Erregen der Mageridrusen. Pfluger's Arch. 1918;170:260–312
  23. Lim RK. The question of a gastrin hormone. Q J Exp Physiol. 1922;13:79–103
  24. Orbeli L. Secretory potential of gastric mucosal extracts. Arch Sci Biol (St. Petersburg). 1907;12:71–93
  25. Emsman M. Uber hamatogene Erregung Von Magenseknetion durch salzsanne Extrakte der Grossen drusigen Organe des Korpens Und des Darminhaltes. Int Beitr z Pathol u Therap d Drahaungstorungen. 1912;3:117–135
  26. Keeton R, Koch F. The distribution of gastrin in the body. Am J Physiol. 1915;37:481–504
  27. Popielski L. The physiological and chemical properties of Witte Peptone. Pfluger's Arch. 1909;128:222–225
  28. Zeliony GP. Non-normal gastric secretion. Arch Sci Biol (St. Petersburg). 1913;17:425–437
  29. Dale HH, Laidlaw PP. Physiological action of β-iminazolyethylamine. J Physiol. 1910;41:318–344
  30. Koch FC, Luckhandt AB, Keeton RW. Gastrin studies. Am J Physiol. 1920;52:508–520
  31. Ivy A, Farrell J. Proof of a humoral mechanism of gastric secretion. Am J Physiol. 1925;74:639–649
  32. Lim RK, Loo L. Gastric secretion. Chin J Physiol. 1927;1:51–82
  33. Necheles H, Lim R. Demonstration of a gastric secretory exitant in circulating blood by vivi-dialysis. Proc Soc Exp Biol Med (NY). 1927;24:197–213
  34. Best CH, McHenry E. Disappearance of histamine from autolysis lung tissue. J Physiol. 1929;67:256–263
  35. Sacks J, Ivy A, Burgess J, Vandolah J. Histamine as the hormone for gastric secretion. Am J Physiol. 1932;101:331–338
  36. Gavin G, McHenry E, Wilson M. Histamine in canine gastric tissues. J Physiol. 1933;79:234–238
  37. Komarov SA. Gastrin. Soc Exp Biol Med. 1938;38:514–516
  38. Ivy A. Mechanism of gastric secretion. Surgery. 1941;10:861–878
  39. Grossman M. Gastrointestinal hormones. Physiol Rev. 1950;30:33–90
  40. Uvnas B. The gastric secretory exitant from the pyloric mucosa. Acta Physiol Scand. 1943;6:97–107
  41. Jorpes J, Jailing O, Mutt V. A method for the preparation of gastrin. Biochem J. 1952;52:327–328
  42. Gregory R, Tracy H. The preparation and properties of gastrin. J Physiol. 1959;149:70–71
  43. Gregory R, Tracy H. Preparation and properties of gastrin. J Physiol. 1961;156:523–543
  44. Gregory R, Hardy P, Jones D, et al. Structure of gastrin. Nature. 1964;204:931–933
  45. Anderson J, Barton M, Gregory R, et al. Synthesis of gastrin. Nature. 1964;204:933–935
  46. Grossman M, Tracy H, Gregory R. Isolation of a gastrin-like substance from the primary and secondary tumor. Gastroenterology. 1961;41:87–91
  47. Yalow R, Berson S. Size and charge distinctions between endogenous human plasma gastrin in peripheral blood and heptadecapeptide gastrins. Gastroenterology. 1970;58:609–615
  48. Gregory R, Tracy H. Isolation of two “big gastrins” from Zollinger-Ellison tumor tissue. Lancet. 1972;2:797–799
  49. Yalow R, Berson S. And now “big-big” gastrin. Biochem Biophys Res Commun. 1972;48:391–395
  50. Rehfeld JF. Three components of gastrin in human serum: gel filtration studies on the molecular size of immunoreactive serum gastrin. Biochim Biophys Acta. 1972;285:364–372
  51. Gregory R, Tracy H. Isolation of two mini-gastrins from Zollinger-Ellison tumor tissue. Gut. 1974;15:683–685
  52. Rehfeld J. Gastrin heterogeneity in serum and tissue. In:  Thompson JC editors. G.I. Hormones. Austin: University of Texas Press; 1975;p. 43–57
  53. Ito R, Sato K, Helmer T, et al. Structural analysis of the gene encoding human gastrin: the large intron contains an Alu sequence. Proc Natl Acad of Sci USA. 1984;81:4662–4666
  54. Yoo OJ, Powell CT, Agarwal KL. Molecular cloning and nucleotide sequence of full length gastrin cDNA coding for porcine gastrin. Proc Natl Acad Sci USA. 1982;79:1049–1057
  55. Wiborg O, Berglund L, Boel E, et al. Structure of the human gastrin gene. Proc Natl Acad Sci USA. 1984;81:1067–1074
  56. Varro A, Ardill JE. Gastrin: an analytical review. Ann Clin Biochem. 2003;40:472–480
  57. Rehfeld JF, Johnsen AH. Identification of gastrin component 1 as gastrin-71 (The largest possible bioactive progastrin product). Eur J Biochem. 1994;223:765–773
  58. Jackson BM, Reeder DD, Thompson JC. Dynamic characteristics of gastrin release. Am J Surg. 1972;123:137–146
  59. Ganguli PC. The effect of protein, carbohydrate, or fat on plasma gastrin concentration in human subjects. Gut. 1970;11:1061
  60. Feldman M, Richardson CT, Taylor IL, et al. Effect of atropine on vagal release of gastrin and pancreatic polypeptide. J Clin Invest. 1979;63:294–298
  61. McGuigan JE, Trudeau WL. Serum gastrin levels before and after vagotomy or pyloroplasty and antrectomy. N Engl J Med. 1972;286:184–188
  62. Hollinshead JW, Debas HT, Yamada T, et al. Hypergastrinemia develops within 24 hours of truncal vagotomy in dogs. Gastroenterology. 1985;88(1 Pt 1):35–40
  63. Raptis S, Dollinger HC, von Berger L, et al. Effects of somatostatin on gastric secretion and gastrin release in man. Digestion. 1975;13:15–26
  64. Jensen RT. Overview of chronic diarrhea caused by functional neuroendocrine neoplasms [review]. Semin Gastrointest Dis. 1999;10:156–172
  65. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome (Clinical presentation in 261 patients). Medicine. 2000;79:379–411
  66. Zollinger RM, Grant GN. Ulcerogenic tumor of the pancreas. JAMA. 1964;190:93–96
  67. Corleto VD, Annibale B, Gibril F. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?. Gastroenterology. 1999;116:A1117
  68. Ellison EC, Sparks JS. Zollinger-Ellison syndrome in the era of effective acid suppression: are we unknowingly growing tumors?. Am J Surg. 2003;186:245–248
  69. Corleto VD, Delle Fave G, Jensen RT. Molecular insights into gastrointestinal neuroendocrine tumours: importance and recent advances. Dig Liver Dis. 2002;34:668–680
  70. Gartner W, Mineva I, Daneva T, et al. A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients. Hum Genet. 2005;117:143–153
  71. Evers BM, Radt PL, Sandoval K. Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene. Ann Surg. 1994;219:596–604
  72. Goebel SU, Iwamoto M, Raffeld M, et al. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Cancer Res. 2002;62:3702–3710
  73. Speel EJ, Richter L, Moch H, et al. Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol. 1999;155:1787–1794
  74. Guru SC, Goldsmith PK, Burns AL, et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci USA. 1998;95:1630–1634
  75. Pritchard DM. Pathogenesis of gastrinomas associated with multiple endocrine neoplasia type 1. Gut. 2007;56:606–607
  76. Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer. 2005;5:367–375
  77. Crabtree JS, Scacheri PC, Ward JM, et al. A mouse model of multiple endocrine neoplasia type 1 develops multiple endocrine tumors. Pro Natl Acad Sci USA. 2001;98:118–123
  78. Bertolino P, Tong WM, Galendo D, et al. Heterozygous MEN1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol Endocrinol. 2003;17:1880–1892
  79. Loffler KA, Biondi CA, Gartside M, et al. Broad tumor spectrum in a mouse of multiple endocrine neoplasia type 1. Int J Cancer. 2007;120:259–267
  80. Marx SJ, Agarwal SK, Heppner C, et al. The gene for multiple endocrine neoplasia type 1: recent findings. Bone. 1999;25:119–122
  81. Zhuang Z, Vortmeyer AO, Pack S, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res. 1997;57:4682–4686
  82. Debelenko LV, Zhuang Z, Emmert-Buck MR, et al. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res. 1997;57:2238–2243
  83. Sawicki MP, Wan YJ, Johnson CL, et al. Loss of heterozygosity on chromosome 11 in sporadic gastrinomas. Hum Genet. 1992;89:445–449
  84. Eubanks PJ, Sawicki MP, Samara GJ, et al. Putative tumor-suppressor gene on chromosome 11 is important in sporadic endocrine tumors. Am J Surg. 1994;167:180–185
  85. Goebel SU, Heppner C, Burns AL, et al. Genotype/phenotype correlation of multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas. J Clin Endocrinol Metab. 2000;85:116–123
  86. Cavallari I, D'Agostino DM, Ferro T, et al. In situ analysis of human menin in normal and neoplastic pancreatic tissues: evidence for differential expression in exocrine and endocrine cells. J Clin Endocrinol Metab. 2003;88:3893–3901
  87. Anlauf M, Schlenger R, Perren A, et al. Microadenomatosis of the endocrine pancreas in patients with and without multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol. 2006;30:560–574
  88. Vortmeyer AO, Huange S, Lubensky I, et al. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab. 2004;89:1934–1938
  89. Anlauf M, Perren A, Meyer CL, et al. Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Gastroenterology. 2005;128:1187–1198
  90. Chung DC, Smith AP, Louis DN, et al. Analysis of the retinoblastoma tumor suppressor gene in pancreatic endocrine tumors. Clin Endocrinol (Oxf). 1997;47:523–528
  91. Bartsch D, Hahn SA, Danichevski KD, et al. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene. 1999;18:2367–2371
  92. Serrano J, Goebel SU, Peghini PL, et al. Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab. 2000;85:4146–4156
  93. Muscarella P, Melvin WS, Fisher WE, et al. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res. 1998;58:237–240
  94. Furukawa M, Raffeld M, Mateo C, et al. Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clin Cancer Res. 2005;11:3233–3242
  95. Terris B, Scoazeck JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumors. Histopathology 1198;32:133-8.
  96. Yu F, Jensen RT, Lubensky IA, et al. Survey of genetic alterations in gastrinomas. Cancer Res. 2000;60:5536–5542
  97. Chen YJ, Vortmeyer A, Zhuang Z, et al. Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance. Cancer Res. 2003;63:817–823
  98. Wild A, Langer P, Celik I, et al. Chromosome 22q in pancreatic endocrine tumors: identification of a homozygous deletion and potential prognostic associations of allelic deletions. Eur J Endocrinol. 2002;147:507–513
  99. Chen YJ, Vortmeyer A, Zhuang Z, et al. Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance. Cancer Res. 2003;63:817–823
  100. Long SH, Berna MJ, Thill M, et al. Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results. J Clin Endocrinol Metab. 2007;92:4394–4402
  101. Papotti M, Bongiovanni , Volante M, et al. Expresion of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. Virchows Arch. 2002;440:461–475
  102. Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I (Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature). Medicine. 2006;85:295–330
  103. Hansky J, Soveny C, Korman MG. Effect of secretin on serum gastrin as measured by radioimmunoassay. Gastroenterology. 1971;61:62–68
  104. Ellison EC, Gower WR, Elkhammas E, et al. Characterization of the in vivo and in vitro inhibition of gastrin secretion from gastrinoma by a somatostatin analogue. Am J Med. 1986;81:56–64
  105. Berna MJ, Hoffmann KM, Long SH, et al. Serum gastrin in Zollinger-Ellison syndrome: II (Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features). Medicine. 2006;85:331–364
  106. Shibata C, Funayama Y, Fukushima K, et al. The glucagon provocative test for the diagnosis and treatment of Zollinger-Ellison syndrome. J Gastrointest Surg. 2008;12:344–349
  107. Howard TJ, Sawicki M, Lewin KJ, et al. Pancreatic polypeptide immunoreactivity in sporadic gastrinoma: relationship to intraabdominal location. Pancreas. 1995;11:350–356
  108. Mutch MG, Frisella MM, DeBenedetti MK, et al. Pancreatic polypeptide is a useful plasma marker for radiographically evident pancreatic islet cell tumors in patients with multiple endocrine neoplasia type 1. Surgery. 1997;122:1012–1019
  109. Syversen U, Mignon M, Bonfils S, et al. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncol. 1993;32:161–165
  110. Hirschowitz BI, Worthington J, Mohnen J, et al. Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia. Aliment Pharmacol Ther. 2007;26:869–878
  111. Abou-Saif A, Gibril F, Ojeaburu JV, et al. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer. 2003;98:249–261
  112. Goebel SU, Serrano J, Yu F, et al. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer. 1999;85:1470–1483
  113. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature [review]. Medicine. 2004;83:43–83Erratum in: Medicine 2004;83:175
  114. Melvin WS, Johnson JA, Sparks J, et al. Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia. Surgery. 1993;114:1183–1188
  115. Karges W, Schaaf L, Dralle H, et al. Concepts for screening and diagnostic follow-up in multiple endocrine neoplasia type 1 (MEN1). Exp Clin Endocrinol Diabetes. 2000;108:334–340
  116. Cardinal J, Bergman N, Hayward N, et al. A report of a national mutation testing service for the MEN1 gene: clinical presentations and implications. J Med Genet. 2005;42:69–74
  117. Noone TC, Hosey J, Firat Z, et al. Imaging and localization of islet-cell tumors of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab. 2005;19:195–211
  118. Imamura M, Minematsu S, Tobe T, Adachi H, Takahashi K. Selective arterial secretin injection test for localization of gastrinoma. Nippon Geka Gakkai Zasshi. 1986;87:671–679
  119. Imamura M, Takahashi K, Adachi H, et al. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Ann Surg. 1987;205:230–239
  120. Doppman JL, Miller DL, Chang R, et al. Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology. 1990;174:25–29
  121. Turner JJ, Wren AM, Jackson JE, et al. Localization of gastrinomas by selective intra-arterial calcium injection. Clin Endocrinol (Oxf). 2002;57:821–825
  122. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity, compared with that of other imaging methods in detecting primary and metastatic gastrinomas (A prospective study). Ann Intern Med. 1996;125:26–34
  123. Alexander HR, Fraker DL, Norton JA, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg. 1998;228:228–238
  124. Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341:635–644
  125. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240:757–773
  126. Norton JA, McLean AM, Fairclogh PD. Endoscopic ultrasound in the localization of pancreatic islet cell tumors. Best Pract Res Clin Endocrinol Metab. 2004;19:177–193
  127. Anderson MA, Carpenter S, Thompson NW, et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95:2271–2277
  128. Hayasaka K, Nihashi T, Matsuura T, et al. Usefulness of F-18 FDG-PET in detection of multiple endocrine tumors with duodenal carcinoid. Comput Med Imaging Graph. 2007;31:191–194
  129. Nakamoto Y, Higashi T, Sakahara H, et al. Evaluation of pancreatic islet cell tumors by fluorine-18 fluordeoxyglucose positron emission tomography: comparison with other modalities. Clin Nucl Med. 2000;25:115–119
  130. Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006;98:4–19
  131. Peghini PL, Annibale B, Azzoni C, et al. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology. 2002;123:68–85
  132. Metz DC, Benya RV, Fishbein VA, et al. Prospective study of the need for long-term antisecretory therapy in patients with Zollinger-Ellison syndrome following successful curative gastrinoma resection. Aliment Pharmacol Ther. 1993;7:247–257
  133. Termanini B, Gibril F, Sutliff VE, et al. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med. 1998;104:422–430
  134. Stewart CA, Termanini B, Sutliff VE, Corleto VD, Weber HC, Gibril F, et al. Management of the Zollinger-Ellison syndrome in pregnancy. Am J Obstet Gynecol. 1997;76:224–233
  135. Mayer A, Sheiner E, Holcberg G. Zollinger-Ellison syndrome, treated with lansoprazole, during pregnancy. Arch Gynecol Obstet. 2007;276:171–173
  136. Wilson SD. Zollinger-Ellison syndrome in children: a 25-year follow-up. Surgery. 1991;110:696–702
  137. Tomassetti P, Salomone T, Migliori M, Campana D, Corinaldesi R. Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients. Drugs Aging. 2003;20:1019–1034
  138. Ellison EC, Sparks J, Verducci JS, et al. 50-year appraisal of gastrinoma: recommendations for staging and treatment. J Am Coll Surg. 2006;202:897–905
  139. Thompson NW, Pasieka J, Fukuuchi A. Duodenal gastrinomas, duodenotomy, and duodenal exploration in the surgical management of Zollinger-Ellison syndrome. World J Surg. 1993;17:455–462
  140. Zogakis TG, Gibril F, Libutti SK, Norton JA, White DE, Jensen RT, et al. Management and outcome of patients with sporadic gastrinoma arising in the duodenum. Ann Surg. 2003;238:42–48
  141. Norton JA. Surgery and prognosis of duodenal gastrinoma as a duodenal neuroendocrine tumor. Best Pract Res Clin Gastroenterol. 2005;19:699–704
  142. Herrmann ME, Ciesla MC, Chejfec G, DeJong SA, Yong SL. Primary nodal gastrinomas. Arch Pathol Lab Med. 2000;124:832–835
  143. Perrier ND, Batts KP, Thompson GB, et al. An immunohistochemical survey for neuroendocrine cells in regional pancreatic lymph nodes: a plausible explanation for primary nodal gastrinomas. Surgery. 1995;118:957–965
  144. Arnold WS, Fraker DL, Alexander HR, et al. Apparent lymph node primary gastrinoma. Surgery. 1994;116:1123–1130
  145. Müssig K, Wehrmann M, Horger M, Bares R, Häring HU, Gallwitz B, et al. Lymph node gastrinoma in multiple endocrine neoplasia type 1—a diagnostic challenge. Exp Clin Endocrinol Diabetes. 2008;Apr 1 [Epub ahead of print]
  146. Anlauf M, Enosawa T, Henopp T, Schmitt A, Gimm O, Brauckhoff M, et al. Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor. Am J Surg Pathol. 2008;32:1101–1105
  147. Ellison EC. Forty-year appraisal of gastrinoma: back to the future. Ann Surg. 1995;222:511–524
  148. Noda S, Norton JA, Jensen RT, Gay WA. Surgical resection of intracardiac gastrinoma. Ann Thorac Surg. 1999;67:532–533
  149. Liu TH, Zhong SX, Chen YF, Lin Y, Chen J, Li DC, et al. Gastric gastrinoma. Chin Med J (Engl). 1989;102:774–782
  150. Primrose JN, Maloney M, Wells M, Bulgim O, Johnston D. Gastrin-producing ovarian mucinous cystadenomas: a cause of the Zollinger-Ellison syndrome. Surgery. 1988;104:830–833
  151. Hirasawa K, Yamada M, Kitagawa M, Takehira Y, Tamakoshi K, Nakamura T, et al. Ovarian mucinous cystadenocarcinoma as a cause of Zollinger-Ellison syndrome: report of a case and review of the literature. Am J Gastroenterol. 2000;95:1348–1351
  152. Abboud P, Bart H, Mansour G, Pinteaux A, Birembaut P. Ovarian gastrinoma in multiple endocrine neoplasia type I: a case report. Am J Obstet Gynecol. 2001;184:237–238
  153. Smith AL, Auldist AW. Successful surgical resection of an hepatic gastrinoma in a child. J Pediatr Gastroenterol Nutr. 1984;3:801–804
  154. Kanakia RR, Sawant PD, Nanivadekar SA, Vishwanath N, Rajagopalan K, Shroff CP. Primary gastrinoma of the liver. Indian Pediatr. 1994;31:1137–1140
  155. Díaz R, Aparicio J, Pous S, Dolz JF, Calderero V. Primary hepatic gastrinoma. Dig Dis Sci. 2003;48:1665–1667
  156. Joshi VV, Nord KS, Hanna M. Renal gastrinoma. Fetal Pediatr Pathol. 1986;6:475–476
  157. Martignoni ME, Friess H, Lübke D, et al. Study of a primary gastrinoma in the common hepatic duct—a case report. Digestion. 1999;60:187–190
  158. Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006;244:410–419
  159. Gibril F, Venzon DJ, Ojeaburu JV, et al. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab. 2001;86:5282–5293
  160. Norton JA, Alexander HR, Fraker DL, et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg. 2001;234:495–505
  161. MacFarlane MP, Fraker DL, Alexander HR, et al. Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery. 1995;118(6):973–979discussion 979-80.
  162. Hausman MS, Thompson NW, Gauger PG, et al. The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery. 2004;136:1205–1211
  163. Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease (Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both). J Intern Med. 1998;243:495–500
  164. Tonelli F, Fratini G, Nesi G, et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg. 2006;244:61–70
  165. Bartsch DK, Fendrich V, Langer P, et al. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg. 2005;242:757–764
  166. Roche A, Girish BV, de Baere T, et al. Prognostic factors for chemoembolization in liver metastasis from endocrine tumors. Hepatogastroenterology. 2004;51:1751–1756
  167. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590–1602
  168. Miller CA, Ellison EC. Therapeutic alternatives in metastatic neuroendocrine tumors. Surg Oncol Clin N Am. 1998;7:863–879
  169. McEntee GP, Nagourney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–1096
  170. Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169:36–42discussion 42-43.
  171. Norton JA, Sugarbaker PH, Doppman JL, et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg. 1986;203:352–359
  172. Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130:677–682
  173. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057–1063
  174. Touzious JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival?. Ann Surg. 2005;241:776–783
  175. Munsunuru S, Chen H, Rajpal S, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg. 2006;141:1000–1004
  176. Landry CS, Scoggins CR, McMasters KM, et al. Management of hepatic metastasis of gastrointestinal carcinoid tumors. J Surg Oncol. 2008;97:253–258
  177. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg. 2002;26:985–990
  178. Mazzaglia PJ, Berber E, Milas M, et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142:10–19
  179. Gillams A, Cassoni A, Conway G, et al. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging. 2005;30:435–441
  180. Lang H, Oldhafer KJ, Weimann A, et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg. 1997;225:347–354
  181. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation. 1998;66:1307–1312
  182. Rosenau J, Bahr MJ, von Wasielewski R, et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation. 2002;73:386–394
  183. Olausson M, Friman S, Herlenius G, et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl. 2007;13:327–333
  184. Pascher A, Klupp J, Neuhaus P. Endocrine tumours of the gastrointestinal tract (Transplantation in the management of metastatic endocrine tumours). Best Pract Res Clin Gastroenterol. 2005;19:637–648
  185. Perry LJ, Stuart K, Stokes KR, et al. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery. 1994;116:1111–1116discussion 1116-7.
  186. Falconi M, Bassi C, Bonora A, et al. Role of chemoembolization in synchronous liver metastases from pancreatic endocrine tumours. Dig Surg. 1999;16:32–38
  187. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg. 2000;190:432–435
  188. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13:572–581
  189. Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol. 2007;188:1201–1207
  190. Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000;95:3276–3281
  191. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–2130
  192. Bilimoria KY, Bentrem DJ, Merkow RP, et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg. 2007;205:558–563
  193. Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247:490–500
  194. Pape UF, Jann H, Müller-Nordhorn J, et al. Progostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113:256–265
  195. Ellison EC. Zollinger-Ellison syndrome: a personal perspective. Am Surg. 2008;74:563–571
  196. Rawson AB, England MT, Gilliam GG, et al. Zollinger-Ellison syndrome with diarrhoea and malabsorption (Observations on a patient before and after pancreatic islet-cell tumour removal without resort to gastric surgery). Lancet. 1960;2:131–134
  197. Parrish JA, Rawline DC. Intestinal mucosa in the Zollinger-Ellison syndrome. Gut. 1965;6:286–289
  198. Waddell WR, Coppinger WR, Loughry RW. Pancreaticoduodenectomy for Zollinger-Ellison syndrome. Ann Surg. 1968;168:641–654
  199. Oberhelman HA. Excisional therapy for ulcerogenic tumors of the duodenum: long-term results. Arch Surg. 1972;104:447–453
  200. Zollinger RM, Ellison EC, Fabri PJ, et al. Primary peptic ulcerations of the jejunum associated with islet cell tumors (Twenty-five-year appraisal). Ann Surg. 1980;192:422–430
  201. Bonfils S, Landor JH, Mignon M, et al. Results of surgical management in 92 consecutive cases with Zollinger-Ellison syndrome. Ann Surg. 1981;194:692–697
  202. Wilson SD. The role of surgery in children with the Zollinger-Ellison syndrome. Surgery. 1982;92:682–692
  203. Friesen SR. Treatment of the Zollinger-Ellison syndrome (A 25 year assessment). Am J Surg. 1982;143:331–338
  204. Wolfe MM, Alexander RW, McGuigan JE. Extrapancreatic extraintestinal gastrinoma: effective treatment by surgery. N Engl J Med. 1982;306:1533–1536
  205. Barreras RF, Mack E, Goodfriend T, Damm M. Resection of gastrinoma in the Zollinger-Ellison syndrome. Gastroenterology. 1982;82:953–956
  206. Malagaleda JR, Edis AJ, Adson MA, et al. Medical and surgical options in the management of patients with gastrinoma. Gastroenterology. 1983;84:1524–1532
  207. Deveney CW, Deveney KS, Way LW. The Zollinger-Ellison syndrome—23 years later. Ann Surg. 1978;188:384–393
  208. Landor JH. Control of the Zollinger-Ellison syndrome by excision of primary and metastatic tumor. Am J Surg. 1984;147:406–409
  209. Stabile BE, Passaro E. Benign and malignant gastrinoma. Am J Surg. 1985;149:144–150
  210. Miyata M, Nakao K, Sakamoto T, et al. Removal of mesenteric gastrinoma: a case report. Surgery. 1986;99:245–248
  211. Vogel SB, Wolfe MM, McGuigan JE, et al. Localization and resection of gastrinomas in Zollinger-Ellison syndrome. Ann Surg. 1987;205:550–556
  212. Howard TJ, Zinner MJ, Stabile BE, Passaro E. Gastrinoma excision for cure (A prospective analysis). Ann Surg. 1990;211:9–14
  213. Kaplan EL, Horvath K, Udekwu A, et al. Gastrinomas: a 42-year experience. World J Surg. 1990;14:365–375discussion 375-6
  214. Declore R, Friesen SR. Rule of pancreatoduodenectomy in the management of primary duodenal wall gastrinomas in patients with Zollinger-Ellison syndrome. Surgery. 1992;112:1016–1022discussion 1022-3
  215. Farley DR, vanHeerden JA, Grant CS, et al. The Zollinger-Ellison syndrome (A collective experience). Ann Surg. 1992;215:561–569discussion 569-70
  216. Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome (Results of a 10-year prospective study). Ann Surg. 1992;215:8–18

PII: S0011-3840(08)00142-1

doi: 10.1067/j.cpsurg.2008.09.001

Current Problems in Surgery
Volume 46, Issue 1 , Pages 13-106 , January 2009

Article Tools

* Image Usage & Resolution